Farley JJ - Search Results

1

FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.

Byrne JM, Waack U, Weinstein EA, Joshi A, Shurland SM, Iarikov D, Bulitta JB, Diep BA, Guina T, Hope WW, Lawrenz MB, Lepak AJ, Luna BM, Miesel L, Phipps AJ, Walsh TJ, Weiss W, Amini T, Farley JJ. Byrne JM, et al. Among authors: farley jj. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01983-20. doi: 10.1128/AAC.01983-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33106262 Free PMC article. Review.

2

Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia.

Waack U, Weinstein EA, Farley JJ. Waack U, et al. Among authors: farley jj. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02242-19. doi: 10.1128/AAC.02242-19. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32122895 Free PMC article. Review.

3

Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability.

Bart SM, Farley JJ, Bala S, Amini T, Cox E. Bart SM, et al. Among authors: farley jj. Clin Infect Dis. 2021 Apr 26;72(8):1422-1428. doi: 10.1093/cid/ciaa246. Clin Infect Dis. 2021. PMID: 32161946

4

An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.

Dheman N, Mahoney N, Cox EM, Farley JJ, Amini T, Lanthier ML. Dheman N, et al. Among authors: farley jj. Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi: 10.1093/cid/ciaa859. Clin Infect Dis. 2021. PMID: 32584952

5

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).

Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, Goodwin A, Jang SH, Iarikov D, Farley J, Nambiar S. Naseer S, et al. Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799. Clin Infect Dis. 2021. PMID: 33393598 Clinical Trial.

6

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Iarikov D, Wassel R, Farley J, Nambiar S. Iarikov D, et al. Infect Dis Ther. 2015 Dec;4(4):433-58. doi: 10.1007/s40121-015-0092-8. Epub 2015 Oct 5. Infect Dis Ther. 2015. PMID: 26437630 Free PMC article.

7

FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.

O'Shaughnessy E, Yasinskaya Y, Dixon C, Higgins K, Moore J, Reynolds K, Ampel NM, Angulo D, Blair JE, Catanzaro A, Galgiani JN, Garvey E, Johnson R, Larwood DJ, Lewis G, Purdie R, Rex JH, Shubitz LF, Stevens DA, Page SJ, Shukla SJ, Farley JJ, Nambiar S. O'Shaughnessy E, et al. Among authors: farley jj. Clin Infect Dis. 2022 Jun 10;74(11):2061-2066. doi: 10.1093/cid/ciab904. Clin Infect Dis. 2022. PMID: 34651656

8

The Integrated Review: FDA Modernizes the Review of New Drug Marketing Applications.

Hearns-Stewart RM, Farley J, Lee KJ, Connelly S, Lowy N, Stein P, Bugin K. Hearns-Stewart RM, et al. Ther Innov Regul Sci. 2021 May;55(3):467-472. doi: 10.1007/s43441-020-00240-1. Epub 2020 Nov 24. Ther Innov Regul Sci. 2021. PMID: 33236259

9

Antibacterial drug development: challenges, recent developments, and future considerations.

Nambiar S, Laessig K, Toerner J, Farley J, Cox E. Nambiar S, et al. Clin Pharmacol Ther. 2014 Aug;96(2):147-9. doi: 10.1038/clpt.2014.116. Clin Pharmacol Ther. 2014. PMID: 25056394 Review.

10

Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.

Thaden JT, Chiswell K, Jaffe I, Bergin SP, Yang WE, Romaine A, Roberts J, Nambiar S, Farley J, Benjamin DK Jr, Smith PB, Tsalik EL. Thaden JT, et al. Pediatrics. 2018 Sep;142(3):e20171849. doi: 10.1542/peds.2017-1849. Pediatrics. 2018. PMID: 30158197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page